Progress in TB Vaccine Development

Ann M. Ginsberg, M.D., Ph.D., is Deputy Director, TB Vaccines in the Global Health Division of the Bill & Melinda Gates Foundation. Dr. Ginsberg has conducted and led TB research and product development programs for 25 years, including 15 years leading and designing clinical strategy for development of TB vaccines and drug regimens of high priority for the developing world. She previously served as the Chief, Respiratory Diseases Branch, NIAID, NIH, as Director, Project Management at Merck Research Laboratories, as Chief Medical Officer at the Global Alliance for TB Drug Development, as Chief Medical Officer at Aeras and as Senior Technical Advisor at IAVI. In these roles, she oversaw in addition to numerous early stage drug and vaccine candidates, the early clinical development program of Pretomanid® and two recent, groundbreaking TB vaccine efficacy trials - of BCG revaccination and M72/AS01E. Dr. Ginsberg has served on numerous national and international advisory committees on vaccines and global health, including the U.S. National Vaccine Advisory Committee. Her undergraduate degree is from Harvard University, her Ph.D. in Molecular Biology from Washington University and her M.D. from Columbia University. She was Board-certified in Anatomic Pathology.